METABOLIC
Tirzepatide
Explore compounded tirzepatide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $169/mo
Injection
Compounded semaglutide injections
Explore compounded semaglutide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
Your treatment plan
From $129/month equivalent
$387 billed every 3 months3-month commitment$149 billed monthly also availableAll fees includedView plan details
- Licensed clinicians
- Compounded by a licensed 503A pharmacy
- No clinic visit
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
Questions before you start?
Compare this treatmentWhat will I pay?
Standard plan price$129 per month equivalent, billed $387 every 3 months. 3-month commitment.
Billing options and renewal
The standard Semaglutide price is $149 billed monthly, or $387 paid up front every three months ($129 per month equivalent; a three-month commitment). These are recurring prices before any eligible first-order discount. A first-order offer reduces that order only; renewal uses the standard price for the chosen plan. A monthly equivalent is not a monthly charge.
What should I know about this treatment?
Explore compounded semaglutide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
Read the evidence and its limitationsWhat should I review before starting?
Boxed warning
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents.
A licensed clinician reviews your health history and medications and determines whether treatment is appropriate for you.
Read the full Important Safety InformationHow do I request Semaglutide online?
Complete the online assessment with your health history, current medications and treatment goals. A licensed clinician reviews the information and decides whether to prescribe. If prescribed, a licensed pharmacy prepares and ships your medication.
See how care worksWhat It Is
Less guesswork. A plan built around you.
When hunger keeps pulling you away from your goals, it is worth discussing the medical options. Semaglutide acts on GLP-1 receptors involved in appetite and glucose regulation.
AnthologyRX offers compounded semaglutide injections. Your independent licensed clinician reviews your health history, medications, goals and any previous GLP-1 treatment, then evaluates whether a compounded preparation meets an individual medical need.
Your plan includes clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging. Your clinician directs dosing and adjustments, while you keep building the nutrition, movement and strength habits that support your goals.
This is a compounded prescription, not an FDA-approved finished drug product. Studies of approved medicines help explain the treatment landscape but do not establish equivalent results for this preparation.
Read the evidenceWho It's For
For people tired of treating appetite like a moral failing.
01
The Willpower Skeptic
You can follow a plan and still find that hunger keeps renegotiating it. You want a clinician to evaluate whether appetite signaling deserves a medical intervention rather than another lecture about discipline.
02
The Plateau Patient
Training and nutrition are still present, but progress has stopped matching the effort. You want the metabolic picture reviewed before the answer becomes simply more restriction.
03
The Restart With History
You have lost weight before and watched the old pattern return. This time you want pharmacology, nutrition, side-effect management, and follow-up to live inside one plan rather than another isolated attempt.
Compounded semaglutide is not an FDA-approved drug product. Candidacy, dose, and whether it belongs alongside anything else you take are determined by a licensed provider from your full intake.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy or planned pregnancy
- Type 1 diabetes or insulin-dependent regimens without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Your Plan
Semaglutide, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Format
- Injection
- Billed amount
- $387 every 3 months
- Monthly equivalent
- $129 per month
- Commitment
- 3 months
- Monthly option
- $149 billed monthly · 1 vial total plan quantity
- Fees
- Included in the plan price
Compounded by a licensed 503A pharmacy
Semaglutide
Injection · Titration program / Ongoing Treatment program
From $129
Monthly equivalent. All fees included.
$387 billed every 3 months. 3-month commitment.
- GLP-1 receptor agonism addressing appetite and glucose signaling
- Provider-directed treatment adjustments based on response and tolerability
- Supportive care considered where clinically appropriate
- Ongoing provider review and messaging access through the care plan
- Prepared to your individual prescription by a licensed 503A pharmacy
$129 /mo equivalent · 3-month commitment
$129/mo equivalent, all-in. Consultation is included in the plan price, not added on top. Consultation, cancellation and refund policy.
What happens when I start?
You'll begin an online assessment for Semaglutide.
- Tell your clinician about you. Share your goals, health history and current medications.
- Review your plan. Confirm the treatment option, billing interval and total shown in the assessment.
- Get an individual clinical review. Your clinician decides whether to prescribe. If prescribed, a licensed pharmacy fulfills your prescription.
Starting an assessment doesn't guarantee a prescription. How care works
Compounded semaglutide and tirzepatide are not FDA-approved products. They are prescribed by licensed clinicians based on individual clinical evaluation and prepared by a licensed 503A pharmacy. Not all patients qualify.
*Price reflects a 3-month commitment. See billing details above.
Your subscription renews at your selected billing interval. Cancel through your member dashboard before the next billing date to stop future charges. Cancellation does not refund the current billing period. See cancellation and refund terms.
Have a question about this plan?
Clinical questions
Message your provider about dosing, side effects, your response or changes in your health.
Open patient portalNew to AnthologyRX? Ask our team about getting started.
Care and cost
Clear pricing. Care that follows through.
Your plan brings the clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging together. The consultation is included in your plan price.
- What will I pay at the start and on renewal?
- $149 billed monthly, or $387 paid up front every three months ($129/month equivalent; three-month commitment). These are the standard recurring prices, before any eligible first-order discount. The monthly equivalent is not a monthly charge.
- Does a dose change affect the price?
- The standard injection price stays the same across the dose stages we currently offer. Your clinician adjusts treatment according to your response and side effects; a higher dose is not a required next step. Moving to a different product or formulation can change the price.
- How is this formulation different?
- Current injectable options combine semaglutide with vitamin B12 or glycine. Your clinician selects the preparation for your needs. Follow the ingredients, concentration and directions on your prescription label. Explore our other semaglutide preparations: Dissolving tablets or Lower-dose injections with B12. Each requires its own clinical evaluation.
- Who helps when I have a question?
- Use the patient portal for questions about dosing, side effects or changes in your health. AnthologyRX support can help with billing, shipping and portal access.
The people behind your care
Guidance from the first question onward.
Independent clinical care
Licensed clinicians affiliated with Arora Health & Aesthetics, LLC review your health history, medications and goals, then discuss whether Semaglutide or another approach fits your needs.
Medical information on this page reviewed by Dr. Dylan Russell, MD, Chief Health Officer on . Your prescribing clinician provides your individual care.
Verify Dr. Russell's medical licensePharmacy quality that matters
Prepared to your prescription by a licensed compounding pharmacy. Our partners have verified quality programs covering identity, potency, independent testing and batch documentation, with sterility and endotoxin controls for injectable preparations.
Compounded preparations are not FDA-approved. Pharmacy quality controls and your clinician's evaluation of treatment evidence each have a role in your care.
Pharmacy & fulfillment
Listed dispensing pharmacy
- BelieveRXFormulation: Semaglutide, injectionVerify: Texas pharmacy license 35264
Availability depends on your prescription and location. For pharmacy questions, contact our team.
A direct line for follow-up
Message your provider through the patient portal about dosing, side effects, your response or changes in your health. Contact AnthologyRX support for billing, shipment or portal-access help.
The Evidence
What the research shows
GLP-1 is a gut hormone released at meals and inactivated extremely rapidly.
30 amino acids
length of the GLP-1 peptide hormone
The detail
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon, released in response to meal intake, and inactivated extremely rapidly by the enzyme dipeptidyl peptidase-4.1
GLP-1 drives glucose-dependent insulin release, slows gastric emptying and promotes satiety.
The detail
As an incretin it is secreted within minutes of nutrient ingestion, and incretin-receptor activation on pancreatic islet beta-cells leads to glucose-dependent insulin secretion, while glucagon-like peptide-1 additionally exerts glucoregulatory action through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion and promotes satiety.2
Semaglutide is a GLP-1 analogue that binds the same receptor as the native hormone.
The same receptor
semaglutide selectively binds and activates the GLP-1 receptor, the target for the native hormone
The detail
Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, the target for the native hormone, and FDA labeling describes the resulting glucose-lowering mechanism as stimulation of insulin secretion and lowering of glucagon secretion, both in a glucose-dependent manner, together with a minor delay in gastric emptying in the early postprandial phase.3
Labeling calls GLP-1 an appetite regulator; the brain findings for semaglutide are from animals.
The detail
FDA labeling further describes glucagon-like peptide-1 as a physiological regulator of appetite and caloric intake, states that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and reports that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.4
Albumin binding gives semaglutide a half-life of about one week, hence weekly dosing.
greater than 99 percent
of semaglutide bound to plasma albumin, the mechanism of protraction
The detail
The pharmacokinetic basis for once-weekly subcutaneous administration is described in the same labeling as albumin binding, identified as the principal mechanism of protraction because it decreases renal clearance and protects against metabolic degradation, with semaglutide extensively bound to plasma albumin at greater than 99 percent, an elimination half-life of approximately one week, and steady-state exposure reached after four to five weekly doses.5
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product: FDA states that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.6
Everything here is mechanism from labeling, not trial results.
The detail
Everything above is drawn from the clinical pharmacology section of FDA labeling, which describes how the molecule acts. This block deliberately stops there rather than reproducing the separate clinical studies section in which trial results for FDA-approved finished drug products are reported, because a described pathway is not a measured outcome.3
The pharmacokinetic numbers describe the approved product, not a compounded preparation.
The brain findings are rodent data, not a measured human response.
The detail
The central nervous system statements above are characterized in labeling as animal findings, and animal data on distribution to brain regions and activation of neurons describe rodent physiology rather than a measured human response.4
FDA calls it a warning sign to claim a compounded drug equals an approved one.
The detail
FDA advises that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and identifies a claim that a compounded drug is the same as an FDA-approved drug as a warning sign for consumers.7
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA-approved semaglutide prescribing information, section 12.1…DailyMed
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.FDA
Important Safety Information
Boxed warning
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
Serious risks
- Pancreatitis
- Gallbladder disease
- Acute kidney injury following the fluid loss that severe vomiting or diarrhea can cause
Commonly reported
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
What most people report is gastrointestinal, most often while the dose is being adjusted. The serious risks are in semaglutide labeling. That warning is why your provider also reviews pancreatitis history, pregnancy plans, and any medication you take that lowers blood sugar. This preparation is compounded rather than an FDA-approved finished drug product, so it has no safety database of its own and your clinician reasons from the labeled risks of the approved products. Those judgments belong to the prescribing clinician, which is the reason this sits with a provider rather than in a shopping cart.
Questions
Asked and answered.
Explore
More in Metabolic.
METABOLIC
Semaglutide + B12 Microdose
A lower-dose compounded semaglutide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $109/mo
METABOLIC
Tirzepatide + B12 Microdose
A lower-dose compounded tirzepatide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $149/mo
